CPHI Milan 2
CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

The Brave New World of Rapid Drug Development

The COVID-19 pandemic has brought the topic of rapid drug development to the forefront of the life sciences sector. Ray Chohan at PatSnap, believes that we have entered the next generation of pharmaceutical development driven by new technology.

Extract:

‘The Brave New World of Rapid Drug Development‘

Before the outbreak of COVID-19, the time taken to develop a new drug or vaccine could take upwards of ten years. Granted, peer reviews, the roll-out of field testing and international approvals were key barriers to speeding up the process, but what is not widely appreciated is the transformation that has taken place in the area of early-stage drug research – specifically where patents and IP are concerned.

In her new book Vaxxers, which discusses the remarkable development of the AstraZeneca vaccine, Professor Sarah Gilbert explains that her team managed to develop the first working vaccine within sixty-five days, simply by trialling novel approaches that had not previously been adopted.

Gilbert stresses that during the development and testing phases of the vaccine, the same precautions that would have been followed during previous new drug trials were taken, but the research phase was effectively streamlined thanks to pioneering new technology. While the concepts of rapid drug development and personalised medicine are far from new, the pharma industry’s sequencing of COVID-19’s DNA in just three days was clearly astounding, marking a defining moment for the life sciences sector and illustrating that the development process can be fast-tracked without compromising on safety.

A key differentiator in the development of the AstraZeneca vaccine was the adoption of new ways of working – namely through the adoption of technology, to reduce research time and increase collaboration between scientists.

While we are not out of the woods yet when it comes to COVID-19, with the race on to stay ahead of new variants and produce a vaccine capable of providing immunity against all betacoronaviruses, we have demonstrated what is possible – and achievable – in terms of rapid drug development.

Click the download button below to read the complete version of  ‘The Brave New World of Rapid Drug Development’ by Ray Chohan at PatSnap

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026